A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)

替扎尼定 医学 不良事件报告系统 不利影响 药理学 麻醉 内科学 痉挛
作者
Lorenzo Villa Zapata,Ainhoa Gómez-Lumbreras,John R. Horn,Malinda Tan,Richard D. Boyce,Daniel C. Malone
出处
期刊:Drug Safety [Adis, Springer Healthcare]
卷期号:45 (8): 863-871 被引量:16
标识
DOI:10.1007/s40264-022-01200-4
摘要

Tizanidine is primarily metabolized via cytochrome P450 (CYP) 1A2 and therefore medications that inhibit the enzyme will affect the clearance of tizanidine, leading to increased plasma concentrations of tizanidine and potentially serious adverse events.Our aim was to study the occurrence of adverse events reported in the FDA Adverse Event Reporting System (FAERS) involving the combination of tizanidine and drugs that inhibit the metabolic activity of CYP1A2.A disproportionality analysis of FAERS reports from 2004 quarter 1 through 2020 quarter 3 was conducted to calculate the reporting odds ratio (ROR) of reports mentioning tizanidine in a suspect or interacting role or having any role, a CYP1A2 inhibitor, and the following adverse events: hypotension, bradycardia, syncope, shock, cardiorespiratory arrest, and fall or fracture.A total of 89 reports were identified mentioning tizanidine, at least one CYP1A2 inhibitor, and one of the adverse events of interest. More than half of the reports identified tizanidine as having a suspect or interacting role (n = 59, 66.3%), and the reports more frequently involved women (n = 58, 65.1%). The median age was 56.1 years (standard deviation 17.1). Some of the important safety signals included interactions between tizanidine in a suspect or interacting role and ciprofloxacin (ROR for hypotension 28.1, 95% confidence interval [CI] 19.2-41.2) or fluvoxamine (ROR for hypotension 36.9, 95% CI 13.1-103.4), and also when reported in "any role" with ciprofloxacin (ROR for hypotension 6.3, 95% CI 4.7-8.5), fluvoxamine (ROR for hypotension 11.4, 95% CI 4.5-28.8), and zafirlukast (ROR for falls 16.0, 95% CI 6.1-42.1).Reports involving tizanidine and a CYP1A2 inhibitor have higher odds of reporting hypotension. This study suggests that concurrent use of tizanidine with CYP1A2 inhibitors may lead to serious health consequences associated with low blood pressure such as falls and fractures.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
kyt_vip完成签到,获得积分10
刚刚
余慵慵完成签到 ,获得积分10
刚刚
一个爱打乒乓球的彪完成签到 ,获得积分10
4秒前
growl发布了新的文献求助10
6秒前
dS3mV4bO5vK7mM8n完成签到,获得积分10
9秒前
hezhiling发布了新的文献求助10
10秒前
sll完成签到 ,获得积分10
11秒前
wing完成签到 ,获得积分10
13秒前
小蘑菇应助科研通管家采纳,获得10
14秒前
有延迟完成签到 ,获得积分10
14秒前
cdercder应助科研通管家采纳,获得10
14秒前
cdercder应助科研通管家采纳,获得10
14秒前
cdercder应助科研通管家采纳,获得10
15秒前
烟花应助科研通管家采纳,获得10
15秒前
15秒前
昵称完成签到 ,获得积分10
17秒前
17秒前
辰12完成签到 ,获得积分10
18秒前
aikeyan完成签到 ,获得积分10
22秒前
lee完成签到 ,获得积分10
28秒前
xia完成签到,获得积分10
30秒前
Paradox完成签到,获得积分10
36秒前
汉堡包应助qqqxun采纳,获得30
39秒前
尿成一条线应助灯座采纳,获得10
40秒前
尿成一条线应助灯座采纳,获得10
40秒前
打打应助灯座采纳,获得10
40秒前
独特的忆彤完成签到 ,获得积分10
40秒前
guo完成签到 ,获得积分10
44秒前
杙北完成签到 ,获得积分10
45秒前
yywang完成签到,获得积分10
47秒前
50秒前
SciGPT应助你听得到采纳,获得10
52秒前
53秒前
孙严青完成签到,获得积分10
54秒前
55秒前
hezhiling发布了新的文献求助10
1分钟前
xinjiasuki完成签到 ,获得积分10
1分钟前
sunnyqqz完成签到,获得积分10
1分钟前
张777粒粒完成签到,获得积分10
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
China Pluperfect I: Epistemology of Past and Outside in Chinese Art 520
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
基于锂离子电池正极材料回收的绿色溶剂开发及工程化应用研究 500
Auslegungsgeschichte 500
Transdermal drug delivery systems market size report 500
Cosmos as Art Object: Studies in Plato's Timaeus and Other Dialogues 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7640634
求助须知:如何正确求助?哪些是违规求助? 9213678
关于积分的说明 19763709
捐赠科研通 7206459
什么是DOI,文献DOI怎么找? 3276117
关于科研通互助平台的介绍 2437790
邀请新用户注册赠送积分活动 2273562